

## Recommendations from York and Scarborough Medicines Commissioning Committee May 2018

	Drug name	Indication	Recommendation, rationale and place in therapy	RAG status	Potential full year cost impact
<b>CCG commissioned Technology Appraisals</b>					
1.	<a href="#">TA518</a> : Tocilizumab for treating giant cell arteritis		<p>Tocilizumab, when used with a tapering course of glucocorticoids (and when used alone after glucocorticoids), is recommended as an option for treating giant cell arteritis in adults, only if:</p> <ul style="list-style-type: none"> <li>• they have relapsing or refractory disease</li> <li>• they have not already had tocilizumab</li> <li>• tocilizumab is stopped after 1 year of uninterrupted treatment at most and</li> <li>• the company provides it with the discount agreed in the patient access scheme</li> </ul>	Red	<p>Except 1-2 patients per year.</p> <p>It is expected that patients will received a max of 1 year of treatment with tocilizumab of 162mg every week.</p> <p>NHS List price is £913.12 for 4 x 162mg syringes.</p> <p>Cost per patient is £11,871 per year based on NHS List price.</p>
<b>NHSE commissioned Technology Appraisals – for noting</b>					
2.	<a href="#">TA517</a> : Avelumab for treating metastatic Merkel cell carcinoma		<p>Avelumab is recommended as an option for treating metastatic Merkel cell carcinoma in adults, only if they have had 1 or more lines of chemotherapy for metastatic disease.</p> <p>Avelumab is recommended for use within the Cancer Drugs Fund as an option for treating metastatic Merkel cell carcinoma in adults, only if:</p> <ul style="list-style-type: none"> <li>• they have not had chemotherapy for metastatic disease and</li> <li>• the conditions in the managed access agreement for avelumab are followed</li> </ul>	Red	No cost impact to CCGs as NHS England commissioned.
3.	<a href="#">TA519</a> : Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy		<p>Pembrolizumab is recommended for use within the Cancer Drugs Fund as an option for treating locally advanced or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy, only if:</p> <ul style="list-style-type: none"> <li>• pembrolizumab is stopped at 2 years of uninterrupted treatment or earlier in the event of disease progression and</li> </ul>	Red	No cost impact to CCGs as NHS England commissioned.

		<ul style="list-style-type: none"> <li>the conditions in the managed access agreement for pembrolizumab are followed.</li> </ul>		
<b>Formulary applications or amendments/pathways/guidelines</b>				
4.	Standardising strengths of high risk unlicensed anti-TB medicines	Ethambutol 400mg in 5ml, Pyrazinamide 500mg in 5ml, Isoniazid 50mg in 5ml approved to be added to the formulary.	Red	No significant cost to CCGs expected.
5.	Bisphosphonates in breast cancer – updated pathway	Approved.	N/A	No significant cost impact expected.
6.	Bisphosphonates medal ranking	<p>The current medal ranking document has been updated; the main changes to this version are :</p> <ul style="list-style-type: none"> <li>the updated prices of the medicines (all have reduced in price except risedronate 5mg tablets which have increased)</li> <li>Alendronic acid 70mg tablets are still 1<sup>st</sup> gold choice – price reduced from £14.69 to £4.92 per year</li> <li>Strontium removed from secondary care options – Discontinued by manufacturer</li> <li>Rationale reviewed and updated</li> <li>Propose to change Zoledronic acid IV to amber specialist recommendation from red, for administration in primary care approved</li> </ul>	N/A	No significant cost impact expected.
7.	Calcium and Vitamin D medal ranking	<p>The current Calcium and Vitamin D Supplements medal ranking document has been updated; the main changes to this version are :</p> <ul style="list-style-type: none"> <li>the updated prices of the medicines</li> <li>Addition of Evacal D3 chewable tab (new 1<sup>st</sup> gold option) and Accrete D3 One a Day chewable tablets.</li> <li>Calceos price has increased from £3.58 to £4.32</li> <li>Updated rationale</li> </ul>	N/A	No significant cost impact expected.

